INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29001, 28386, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29002, 28388, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29003, 28390, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29004, 28391, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29005, 28684, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29006, 481, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29007, 482, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29008, 484, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29009, 2999, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29010, 3000, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29011, 3002, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29012, 3003, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29013, 3004, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29014, 11150, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29015, 11576, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29016, 11578, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29017, 11579, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29018, 11580, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29019, 11581, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29020, 11862, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29021, 11863, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29022, 13885, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29023, 23941, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29024, 23943, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29025, 27880, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29026, 28384, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29027, 28386, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29028, 28388, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29029, 28390, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29030, 28391, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29031, 28684, 'Tramadol', 'Alcoholic Intoxication', 'The CNS depressant effects of tramadol may be additive with those of alcohol and may lead to profound sedation, respiratory depression, coma, and death.  Therapy with tramadol should be administered cautiously (and only when alternative treatment options are inadequate) in patients who might be prone to acute alcohol intake.  Dosages and durations should be limited to the minimum required and patients should be monitored for signs and symptoms of respiratory depression and sedation.  Prescribing naloxone for the emergency treatment of opioid overdose should be considered; naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, but it also increases the risk of seizures.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29032, 481, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29033, 482, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29034, 484, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29035, 2999, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29036, 3000, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29037, 3002, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29038, 3003, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29039, 3004, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29040, 11150, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29041, 11576, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29042, 11578, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29043, 11579, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29044, 11580, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29045, 11581, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29046, 11862, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29047, 11863, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29048, 13885, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29049, 23941, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29050, 23943, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29051, 27880, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29052, 28384, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29053, 28386, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29054, 28388, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29055, 28390, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29056, 28391, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29057, 28684, 'Tramadol', 'Substance-Related Disorders', 'Tramadol exposes patients and other users to the risks of addiction, abuse, and misuse.  Each patient''s risk should be assessed before prescribing tramadol, and all patients should be monitored regularly for development of such behaviors and conditions.  Risks are increased in patients with personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression); the potential for such risks should not prevent proper pain management in any given patient.  Patients at increased risk may be prescribed tramadol, but use in such patients requires intensive counseling about the risks and proper use of tramadol, as well as intensive monitoring for signs of addiction, abuse, and misuse; prescribing naloxone for the emergency treatment of opioid overdose should be considered.Opioids are sought by drug abusers and patients with addiction disorders and are subject to criminal diversion.  These risks should be considered when prescribing or dispensing tramadol.  Strategies to reduce such risks include prescribing the smallest appropriate quantity and advising the patient about proper disposal of unused drug.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29058, 481, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29059, 482, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29060, 484, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29061, 2999, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29062, 3000, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29063, 3002, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29064, 3003, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29065, 3004, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29066, 11150, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29067, 11576, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29068, 11578, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29069, 11579, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29070, 11580, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29071, 11581, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29072, 11862, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29073, 11863, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29074, 13885, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29075, 23941, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29076, 23943, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29077, 27880, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29078, 28384, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29079, 28386, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29080, 28388, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29081, 28390, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29082, 28391, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29083, 28684, 'Tramadol', 'Respiratory Insufficiency', 'Tramadol is contraindicated in patients with significant respiratory depression.  Serious, life-threatening, or fatal respiratory depression may occur with tramadol.  Patients should be monitored closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and after a dosage increase.The use of tramadol in patients with acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment is contraindicated.  Tramadol-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression are at increased risk of decreased respiratory drive (including apnea), even at recommended dosages of tramadol.  In patients who may be susceptible to the intracranial effects of carbon dioxide (CO2) retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure; these patients should be monitored for signs of sedation and respiratory depression, especially when starting tramadol.Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics (or altered clearance) compared to younger, healthier patients.  These patients should be monitored closely, especially when starting and titrating tramadol and when coadministering with other drugs that depress respiration; alternatively, the use of nonopioid analgesics should be considered.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29084, 481, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29085, 482, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29086, 484, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29087, 2999, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29088, 3000, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29089, 3002, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29090, 3003, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29091, 3004, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29092, 11150, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29093, 11576, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29094, 11578, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29095, 11579, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29096, 11580, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29097, 11581, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29098, 11862, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29099, 11863, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29100, 13885, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29101, 23941, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29102, 23943, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29103, 27880, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29104, 28384, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29105, 28386, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29106, 28388, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29107, 28390, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29108, 28391, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29109, 28684, 'Tramadol', 'Gastrointestinal Diseases', 'Tramadol may cause spasm of the sphincter of Oddi.  Opioids may increase serum amylase.  Patients with biliary tract disease (including acute pancreatitis) should be monitored for worsening symptoms.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29110, 481, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29111, 482, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29112, 484, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29113, 2999, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29114, 3000, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29115, 3002, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29116, 3003, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29117, 3004, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29118, 11150, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29119, 11576, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29120, 11578, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29121, 11579, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29122, 11580, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29123, 11581, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29124, 11862, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29125, 11863, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29126, 13885, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29127, 23941, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29128, 23943, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29129, 27880, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29130, 28384, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29131, 28386, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29132, 28388, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29133, 28390, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29134, 28391, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29135, 28684, 'Tramadol', 'Hypoglycemia', 'Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization.  In most cases, patients had predisposing risk factors (e.g., diabetes); caution is recommended in these patients.  If hypoglycemia is suspected, blood glucose levels should be monitored and discontinuation of therapy should be considered as appropriate.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29136, 481, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29137, 482, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29138, 484, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29139, 2999, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29140, 3000, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29141, 3002, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29142, 3003, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29143, 3004, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29144, 11150, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29145, 11576, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29146, 11578, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29147, 11579, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29148, 11580, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29149, 11581, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29150, 11862, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29151, 11863, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29152, 13885, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29153, 23941, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29154, 23943, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29155, 27880, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29156, 28384, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29157, 28386, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29158, 28388, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29159, 28390, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29160, 28391, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29161, 28684, 'Tramadol', 'Hypotension', 'Tramadol may cause severe hypotension (including orthostatic hypotension, syncope) in ambulatory patients.  Risk is increased in patients whose ability to maintain blood pressure has already been compromised by reduced blood volume or coadministration of certain CNS depressant drugs; these patients should be monitored for signs of hypotension after starting or titrating tramadol.  In patients with circulatory shock, tramadol may cause vasodilation that can further reduce cardiac output and blood pressure; tramadol should be avoided in patients with circulatory shock.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29162, 481, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29163, 482, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29164, 484, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29165, 2999, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29166, 3000, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29167, 3002, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29168, 3003, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29169, 3004, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29170, 11150, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29171, 11576, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29172, 11578, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29173, 11579, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29174, 11580, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29175, 11581, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29176, 11862, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29177, 11863, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29178, 13885, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29179, 23941, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29180, 23943, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29181, 27880, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29182, 28384, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29183, 28386, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29184, 28388, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29185, 28390, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29186, 28391, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29187, 28684, 'Tramadol', 'Intracranial Hypertension', 'Opioids may obscure the clinical course in a patient with a head injury.  The use of tramadol should be avoided in patients with impaired consciousness or coma.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29188, 481, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29189, 482, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29190, 484, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29191, 2999, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29192, 3000, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29193, 3002, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29194, 3003, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29195, 3004, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29196, 11150, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29197, 11576, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29198, 11578, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29199, 11579, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29200, 11580, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29201, 11581, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29202, 11862, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29203, 11863, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29204, 13885, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29205, 23941, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29206, 23943, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29207, 27880, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29208, 28384, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29209, 28386, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29210, 28388, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29211, 28390, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29212, 28391, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29213, 28684, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29214, 481, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29215, 482, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29216, 484, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29217, 2999, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29218, 3000, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29219, 3002, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29220, 3003, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29221, 3004, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29222, 11150, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29223, 11576, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29224, 11578, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29225, 11579, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29226, 11580, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29227, 11581, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29228, 11862, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29229, 11863, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29230, 13885, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29231, 23941, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29232, 23943, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29233, 27880, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29234, 28384, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29235, 28386, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29236, 28388, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29237, 28390, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29238, 28391, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29239, 28684, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29240, 481, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29241, 482, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29242, 484, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29243, 2999, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29244, 3000, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29245, 3002, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29246, 3003, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29247, 3004, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29248, 11150, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29249, 11576, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29250, 11578, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29251, 11579, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29252, 11580, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29253, 11581, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29254, 11862, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29255, 11863, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29256, 13885, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29257, 23941, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29258, 23943, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29259, 27880, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29260, 28384, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29261, 28386, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29262, 28388, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29263, 28390, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29264, 28391, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29265, 28684, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29266, 481, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29267, 482, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29268, 484, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29269, 2999, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29270, 3000, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29271, 3002, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29272, 3003, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29273, 3004, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29274, 11150, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29275, 11576, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29276, 11578, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29277, 11579, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29278, 11580, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29279, 11581, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29280, 11862, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29281, 11863, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29282, 13885, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29283, 23941, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29284, 23943, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29285, 27880, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29286, 28384, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29287, 28386, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29288, 28388, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29289, 28390, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29290, 28391, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29291, 28684, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29292, 74, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29293, 81, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29294, 82, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29295, 90, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29296, 91, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29297, 12248, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29298, 13352, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29299, 15595, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29300, 18629, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29301, 18630, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29302, 25942, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29303, 25943, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29304, 29193, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29305, 74, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29306, 81, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29307, 82, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29308, 90, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29309, 91, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29310, 12248, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29311, 13352, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29312, 15595, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29313, 18629, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29314, 18630, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29315, 25942, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29316, 25943, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29317, 29193, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29318, 4373, 'Trastuzumab emtansine', 'Liver Diseases', 'Serious hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases including liver failure and death has been reported in patients treated with the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla).  Cases of nodular regenerative hyperplasia (NRH) of the liver, a rare condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been reported in clinical trials.  If NRH is confirmed, treatment must be permanently discontinued.  Monitor serum transaminases and bilirubin before initiation of treatment and before each dose.  It is recommended to reduce the dose or discontinue therapy with ado-trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin.  In patients with serum transaminases > 3  ULN and concomitant total bilirubin > 2  ULN, permanently discontinue treatment.', '3', '"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29319, 4998, 'Trastuzumab emtansine', 'Liver Diseases', 'Serious hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases including liver failure and death has been reported in patients treated with the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla).  Cases of nodular regenerative hyperplasia (NRH) of the liver, a rare condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been reported in clinical trials.  If NRH is confirmed, treatment must be permanently discontinued.  Monitor serum transaminases and bilirubin before initiation of treatment and before each dose.  It is recommended to reduce the dose or discontinue therapy with ado-trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin.  In patients with serum transaminases > 3  ULN and concomitant total bilirubin > 2  ULN, permanently discontinue treatment.', '3', '"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29320, 20406, 'Trastuzumab emtansine', 'Liver Diseases', 'Serious hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases including liver failure and death has been reported in patients treated with the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla).  Cases of nodular regenerative hyperplasia (NRH) of the liver, a rare condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been reported in clinical trials.  If NRH is confirmed, treatment must be permanently discontinued.  Monitor serum transaminases and bilirubin before initiation of treatment and before each dose.  It is recommended to reduce the dose or discontinue therapy with ado-trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin.  In patients with serum transaminases > 3  ULN and concomitant total bilirubin > 2  ULN, permanently discontinue treatment.', '3', '"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29321, 20407, 'Trastuzumab emtansine', 'Liver Diseases', 'Serious hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases including liver failure and death has been reported in patients treated with the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla).  Cases of nodular regenerative hyperplasia (NRH) of the liver, a rare condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been reported in clinical trials.  If NRH is confirmed, treatment must be permanently discontinued.  Monitor serum transaminases and bilirubin before initiation of treatment and before each dose.  It is recommended to reduce the dose or discontinue therapy with ado-trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin.  In patients with serum transaminases > 3  ULN and concomitant total bilirubin > 2  ULN, permanently discontinue treatment.', '3', '"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29322, 20408, 'Trastuzumab emtansine', 'Liver Diseases', 'Serious hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases including liver failure and death has been reported in patients treated with the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla).  Cases of nodular regenerative hyperplasia (NRH) of the liver, a rare condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been reported in clinical trials.  If NRH is confirmed, treatment must be permanently discontinued.  Monitor serum transaminases and bilirubin before initiation of treatment and before each dose.  It is recommended to reduce the dose or discontinue therapy with ado-trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin.  In patients with serum transaminases > 3  ULN and concomitant total bilirubin > 2  ULN, permanently discontinue treatment.', '3', '"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29323, 20432, 'Trastuzumab emtansine', 'Liver Diseases', 'Serious hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases including liver failure and death has been reported in patients treated with the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla).  Cases of nodular regenerative hyperplasia (NRH) of the liver, a rare condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been reported in clinical trials.  If NRH is confirmed, treatment must be permanently discontinued.  Monitor serum transaminases and bilirubin before initiation of treatment and before each dose.  It is recommended to reduce the dose or discontinue therapy with ado-trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin.  In patients with serum transaminases > 3  ULN and concomitant total bilirubin > 2  ULN, permanently discontinue treatment.', '3', '"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29324, 20433, 'Trastuzumab emtansine', 'Liver Diseases', 'Serious hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases including liver failure and death has been reported in patients treated with the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla).  Cases of nodular regenerative hyperplasia (NRH) of the liver, a rare condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been reported in clinical trials.  If NRH is confirmed, treatment must be permanently discontinued.  Monitor serum transaminases and bilirubin before initiation of treatment and before each dose.  It is recommended to reduce the dose or discontinue therapy with ado-trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin.  In patients with serum transaminases > 3  ULN and concomitant total bilirubin > 2  ULN, permanently discontinue treatment.', '3', '"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29325, 31018, 'Trastuzumab emtansine', 'Liver Diseases', 'Serious hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases including liver failure and death has been reported in patients treated with the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla).  Cases of nodular regenerative hyperplasia (NRH) of the liver, a rare condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been reported in clinical trials.  If NRH is confirmed, treatment must be permanently discontinued.  Monitor serum transaminases and bilirubin before initiation of treatment and before each dose.  It is recommended to reduce the dose or discontinue therapy with ado-trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin.  In patients with serum transaminases > 3  ULN and concomitant total bilirubin > 2  ULN, permanently discontinue treatment.', '3', '"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29326, 4373, 'Trastuzumab emtansine', 'Lung Diseases', 'Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity.  Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis.  Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity.  Patients should be monitored for pulmonary symptoms.  Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.', '3', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29327, 4998, 'Trastuzumab emtansine', 'Lung Diseases', 'Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity.  Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis.  Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity.  Patients should be monitored for pulmonary symptoms.  Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.', '3', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29328, 20406, 'Trastuzumab emtansine', 'Lung Diseases', 'Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity.  Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis.  Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity.  Patients should be monitored for pulmonary symptoms.  Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.', '3', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29329, 20407, 'Trastuzumab emtansine', 'Lung Diseases', 'Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity.  Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis.  Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity.  Patients should be monitored for pulmonary symptoms.  Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.', '3', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29330, 20408, 'Trastuzumab emtansine', 'Lung Diseases', 'Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity.  Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis.  Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity.  Patients should be monitored for pulmonary symptoms.  Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.', '3', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29331, 20432, 'Trastuzumab emtansine', 'Lung Diseases', 'Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity.  Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis.  Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity.  Patients should be monitored for pulmonary symptoms.  Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.', '3', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29332, 20433, 'Trastuzumab emtansine', 'Lung Diseases', 'Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity.  Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis.  Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity.  Patients should be monitored for pulmonary symptoms.  Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.', '3', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29333, 31018, 'Trastuzumab emtansine', 'Lung Diseases', 'Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity.  Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis.  Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity.  Patients should be monitored for pulmonary symptoms.  Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.', '3', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29334, 4373, 'Trastuzumab emtansine', 'Heart Failure', 'Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity.  Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF.  Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions.  Evaluate cardiac function before, during, and upon completion of treatment.  Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further.  It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29335, 4998, 'Trastuzumab emtansine', 'Heart Failure', 'Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity.  Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF.  Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions.  Evaluate cardiac function before, during, and upon completion of treatment.  Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further.  It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29336, 20406, 'Trastuzumab emtansine', 'Heart Failure', 'Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity.  Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF.  Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions.  Evaluate cardiac function before, during, and upon completion of treatment.  Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further.  It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29337, 20407, 'Trastuzumab emtansine', 'Heart Failure', 'Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity.  Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF.  Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions.  Evaluate cardiac function before, during, and upon completion of treatment.  Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further.  It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29338, 20408, 'Trastuzumab emtansine', 'Heart Failure', 'Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity.  Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF.  Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions.  Evaluate cardiac function before, during, and upon completion of treatment.  Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further.  It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29339, 20432, 'Trastuzumab emtansine', 'Heart Failure', 'Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity.  Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF.  Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions.  Evaluate cardiac function before, during, and upon completion of treatment.  Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further.  It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29340, 20433, 'Trastuzumab emtansine', 'Heart Failure', 'Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity.  Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF.  Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions.  Evaluate cardiac function before, during, and upon completion of treatment.  Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further.  It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29341, 31018, 'Trastuzumab emtansine', 'Heart Failure', 'Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity.  Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF.  Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions.  Evaluate cardiac function before, during, and upon completion of treatment.  Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further.  It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29342, 4373, 'Trastuzumab emtansine', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of agents that block HER2 activity.  Patients experiencing peripheral neuropathy may require temporary interruption, dose reduction, or treatment discontinuation of these agents.  Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy until resolution.  Close monitoring is recommended when using these agents in patients at risk, and all patients should be monitored on an ongoing basis for signs or symptoms of neurotoxicity.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29343, 4998, 'Trastuzumab emtansine', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of agents that block HER2 activity.  Patients experiencing peripheral neuropathy may require temporary interruption, dose reduction, or treatment discontinuation of these agents.  Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy until resolution.  Close monitoring is recommended when using these agents in patients at risk, and all patients should be monitored on an ongoing basis for signs or symptoms of neurotoxicity.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29344, 20406, 'Trastuzumab emtansine', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of agents that block HER2 activity.  Patients experiencing peripheral neuropathy may require temporary interruption, dose reduction, or treatment discontinuation of these agents.  Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy until resolution.  Close monitoring is recommended when using these agents in patients at risk, and all patients should be monitored on an ongoing basis for signs or symptoms of neurotoxicity.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29345, 20407, 'Trastuzumab emtansine', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of agents that block HER2 activity.  Patients experiencing peripheral neuropathy may require temporary interruption, dose reduction, or treatment discontinuation of these agents.  Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy until resolution.  Close monitoring is recommended when using these agents in patients at risk, and all patients should be monitored on an ongoing basis for signs or symptoms of neurotoxicity.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29346, 20408, 'Trastuzumab emtansine', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of agents that block HER2 activity.  Patients experiencing peripheral neuropathy may require temporary interruption, dose reduction, or treatment discontinuation of these agents.  Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy until resolution.  Close monitoring is recommended when using these agents in patients at risk, and all patients should be monitored on an ongoing basis for signs or symptoms of neurotoxicity.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29347, 20432, 'Trastuzumab emtansine', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of agents that block HER2 activity.  Patients experiencing peripheral neuropathy may require temporary interruption, dose reduction, or treatment discontinuation of these agents.  Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy until resolution.  Close monitoring is recommended when using these agents in patients at risk, and all patients should be monitored on an ongoing basis for signs or symptoms of neurotoxicity.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29348, 20433, 'Trastuzumab emtansine', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of agents that block HER2 activity.  Patients experiencing peripheral neuropathy may require temporary interruption, dose reduction, or treatment discontinuation of these agents.  Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy until resolution.  Close monitoring is recommended when using these agents in patients at risk, and all patients should be monitored on an ongoing basis for signs or symptoms of neurotoxicity.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29349, 31018, 'Trastuzumab emtansine', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of agents that block HER2 activity.  Patients experiencing peripheral neuropathy may require temporary interruption, dose reduction, or treatment discontinuation of these agents.  Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy until resolution.  Close monitoring is recommended when using these agents in patients at risk, and all patients should be monitored on an ongoing basis for signs or symptoms of neurotoxicity.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29350, 4373, 'Trastuzumab emtansine', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of agents that block HER2 activity.  Monitor platelet counts prior to initiation of therapy and prior to each dose.  If appropriate modify the dose according to clinical guidelines.  Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29351, 4998, 'Trastuzumab emtansine', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of agents that block HER2 activity.  Monitor platelet counts prior to initiation of therapy and prior to each dose.  If appropriate modify the dose according to clinical guidelines.  Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29352, 20406, 'Trastuzumab emtansine', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of agents that block HER2 activity.  Monitor platelet counts prior to initiation of therapy and prior to each dose.  If appropriate modify the dose according to clinical guidelines.  Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29353, 20407, 'Trastuzumab emtansine', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of agents that block HER2 activity.  Monitor platelet counts prior to initiation of therapy and prior to each dose.  If appropriate modify the dose according to clinical guidelines.  Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29354, 20408, 'Trastuzumab emtansine', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of agents that block HER2 activity.  Monitor platelet counts prior to initiation of therapy and prior to each dose.  If appropriate modify the dose according to clinical guidelines.  Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29355, 20432, 'Trastuzumab emtansine', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of agents that block HER2 activity.  Monitor platelet counts prior to initiation of therapy and prior to each dose.  If appropriate modify the dose according to clinical guidelines.  Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29356, 20433, 'Trastuzumab emtansine', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of agents that block HER2 activity.  Monitor platelet counts prior to initiation of therapy and prior to each dose.  If appropriate modify the dose according to clinical guidelines.  Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29357, 31018, 'Trastuzumab emtansine', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of agents that block HER2 activity.  Monitor platelet counts prior to initiation of therapy and prior to each dose.  If appropriate modify the dose according to clinical guidelines.  Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29358, 74, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29359, 81, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29360, 82, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29361, 90, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29362, 91, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29363, 12248, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29364, 13352, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29365, 15595, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29366, 18629, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29367, 18630, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29368, 25942, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29369, 25943, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29370, 29193, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29371, 74, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29372, 81, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29373, 82, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29374, 90, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29375, 91, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29376, 12248, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29377, 13352, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29378, 15595, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29379, 18629, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29380, 18630, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29381, 25942, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29382, 25943, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29383, 29193, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '"Product Information. Vesanoid (tretinoin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29384, 6838, 'Triamcinolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29385, 6840, 'Triamcinolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29386, 11634, 'Triamcinolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29387, 23270, 'Triamcinolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29388, 28461, 'Triamcinolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29389, 6838, 'Triamcinolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29390, 6840, 'Triamcinolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29391, 11634, 'Triamcinolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29392, 23270, 'Triamcinolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29393, 28461, 'Triamcinolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29394, 6838, 'Triamcinolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29395, 6840, 'Triamcinolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29396, 11634, 'Triamcinolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29397, 23270, 'Triamcinolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29398, 28461, 'Triamcinolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29399, 6838, 'Triamcinolone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29400, 6840, 'Triamcinolone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29401, 11634, 'Triamcinolone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29402, 23270, 'Triamcinolone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29403, 28461, 'Triamcinolone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29404, 6838, 'Triamcinolone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29405, 6840, 'Triamcinolone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29406, 11634, 'Triamcinolone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29407, 23270, 'Triamcinolone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29408, 28461, 'Triamcinolone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29409, 6838, 'Triamcinolone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29410, 6840, 'Triamcinolone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29411, 11634, 'Triamcinolone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29412, 23270, 'Triamcinolone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29413, 28461, 'Triamcinolone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29414, 6838, 'Triamcinolone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29415, 6840, 'Triamcinolone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29416, 11634, 'Triamcinolone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29417, 23270, 'Triamcinolone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29418, 28461, 'Triamcinolone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29419, 6838, 'Triamcinolone', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29420, 6840, 'Triamcinolone', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29421, 11634, 'Triamcinolone', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29422, 23270, 'Triamcinolone', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29423, 28461, 'Triamcinolone', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29424, 6838, 'Triamcinolone', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29425, 6840, 'Triamcinolone', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29426, 11634, 'Triamcinolone', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29427, 23270, 'Triamcinolone', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29428, 28461, 'Triamcinolone', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29429, 6838, 'Triamcinolone', 'Hyperlipidemias', 'Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods.  Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42|"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29430, 6840, 'Triamcinolone', 'Hyperlipidemias', 'Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods.  Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42|"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29431, 11634, 'Triamcinolone', 'Hyperlipidemias', 'Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods.  Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42|"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29432, 23270, 'Triamcinolone', 'Hyperlipidemias', 'Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods.  Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42|"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29433, 28461, 'Triamcinolone', 'Hyperlipidemias', 'Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods.  Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42|"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29434, 6838, 'Triamcinolone', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29435, 6840, 'Triamcinolone', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29436, 11634, 'Triamcinolone', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29437, 23270, 'Triamcinolone', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29438, 28461, 'Triamcinolone', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29439, 6838, 'Triamcinolone', 'Liver Diseases', 'Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|Cunliffe WJ, Burton JL, Holti G, Wright V "Hazards of steroid therapy in hepatic failure." Br J Dermatol 93 (1975):  183-5|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29440, 6840, 'Triamcinolone', 'Liver Diseases', 'Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|Cunliffe WJ, Burton JL, Holti G, Wright V "Hazards of steroid therapy in hepatic failure." Br J Dermatol 93 (1975):  183-5|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29441, 11634, 'Triamcinolone', 'Liver Diseases', 'Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|Cunliffe WJ, Burton JL, Holti G, Wright V "Hazards of steroid therapy in hepatic failure." Br J Dermatol 93 (1975):  183-5|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29442, 23270, 'Triamcinolone', 'Liver Diseases', 'Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|Cunliffe WJ, Burton JL, Holti G, Wright V "Hazards of steroid therapy in hepatic failure." Br J Dermatol 93 (1975):  183-5|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29443, 28461, 'Triamcinolone', 'Liver Diseases', 'Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|Cunliffe WJ, Burton JL, Holti G, Wright V "Hazards of steroid therapy in hepatic failure." Br J Dermatol 93 (1975):  183-5|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29444, 6838, 'Triamcinolone', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29445, 6840, 'Triamcinolone', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29446, 11634, 'Triamcinolone', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29447, 23270, 'Triamcinolone', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29448, 28461, 'Triamcinolone', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29449, 6838, 'Triamcinolone', 'Myasthenia Gravis', 'Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting.  Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages.  Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached).  Improvement may be delayed and gradual.  Thus, it is important not to discontinue therapy prematurely.', '2', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29450, 6840, 'Triamcinolone', 'Myasthenia Gravis', 'Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting.  Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages.  Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached).  Improvement may be delayed and gradual.  Thus, it is important not to discontinue therapy prematurely.', '2', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29451, 11634, 'Triamcinolone', 'Myasthenia Gravis', 'Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting.  Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages.  Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached).  Improvement may be delayed and gradual.  Thus, it is important not to discontinue therapy prematurely.', '2', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29452, 23270, 'Triamcinolone', 'Myasthenia Gravis', 'Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting.  Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages.  Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached).  Improvement may be delayed and gradual.  Thus, it is important not to discontinue therapy prematurely.', '2', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29453, 28461, 'Triamcinolone', 'Myasthenia Gravis', 'Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting.  Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages.  Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached).  Improvement may be delayed and gradual.  Thus, it is important not to discontinue therapy prematurely.', '2', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29454, 6838, 'Triamcinolone', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29455, 6840, 'Triamcinolone', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29456, 11634, 'Triamcinolone', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29457, 23270, 'Triamcinolone', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29458, 28461, 'Triamcinolone', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29459, 6838, 'Triamcinolone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29460, 6840, 'Triamcinolone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29461, 11634, 'Triamcinolone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29462, 23270, 'Triamcinolone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29463, 28461, 'Triamcinolone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29464, 6838, 'Triamcinolone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29465, 6840, 'Triamcinolone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29466, 11634, 'Triamcinolone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29467, 23270, 'Triamcinolone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29468, 28461, 'Triamcinolone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29469, 6838, 'Triamcinolone', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29470, 6840, 'Triamcinolone', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29471, 11634, 'Triamcinolone', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29472, 23270, 'Triamcinolone', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29473, 28461, 'Triamcinolone', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29474, 6838, 'Triamcinolone', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29475, 6840, 'Triamcinolone', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29476, 11634, 'Triamcinolone', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29477, 23270, 'Triamcinolone', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29478, 28461, 'Triamcinolone', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29479, 6838, 'Triamcinolone', 'Scleroderma, Localized', 'In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  Therapy with corticosteroids should be administered cautiously in patients with scleroderma.  In addition, they should be limited to short-term use.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29480, 6840, 'Triamcinolone', 'Scleroderma, Localized', 'In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  Therapy with corticosteroids should be administered cautiously in patients with scleroderma.  In addition, they should be limited to short-term use.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29481, 11634, 'Triamcinolone', 'Scleroderma, Localized', 'In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  Therapy with corticosteroids should be administered cautiously in patients with scleroderma.  In addition, they should be limited to short-term use.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29482, 23270, 'Triamcinolone', 'Scleroderma, Localized', 'In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  Therapy with corticosteroids should be administered cautiously in patients with scleroderma.  In addition, they should be limited to short-term use.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29483, 28461, 'Triamcinolone', 'Scleroderma, Localized', 'In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  Therapy with corticosteroids should be administered cautiously in patients with scleroderma.  In addition, they should be limited to short-term use.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29484, 6838, 'Triamcinolone', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29485, 6840, 'Triamcinolone', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29486, 11634, 'Triamcinolone', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29487, 23270, 'Triamcinolone', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29488, 28461, 'Triamcinolone', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29489, 6838, 'Triamcinolone', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29490, 6840, 'Triamcinolone', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29491, 11634, 'Triamcinolone', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29492, 23270, 'Triamcinolone', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29493, 28461, 'Triamcinolone', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29494, 29805, 'Trabectedin', 'Cardiomyopathies', 'Cardiomyopathy including cardiac failure, congestive heart failure, ejection fraction decreased, diastolic dysfunction, or right ventricular dysfunction can occur with the use of trabectedin.  Care should be taken when using this agent in patients with heart disease.  Assess LVEF before initiation of therapy and at 2- to 3-month intervals thereafter.  It is recommended to withhold therapy for LVEF below lower limit of normal and permanently discontinue treatment for symptomatic cardiomyopathy or persistent left ventricular dysfunction that does not recover to lower limit of normal within 3 weeks.', '2', '"Product Information. Yondelis (trabectedin)." Janssen Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29495, 29805, 'Trabectedin', 'Liver Diseases', 'Hepatotoxicity, including hepatic failure, can occur with the use of trabectedin.  It is recommended to assess liver function test (LFTs) prior to each administration of trabectedin and as deem appropriately based on the severity of preexisting hepatic impairment.  Dose interruption, reduction, or discontinuation of treatment might be appropriate based on severity and duration of LFTs abnormality.  The use of trabectedin in patients with mild hepatic impairment is not expected to cause clinically significant effects on its pharmacokinetics.  Reduce dose in patients with moderate hepatic impairment as clinically appropriate and do not administer trabectedin to patients with severe hepatic impairment (bilirubin levels above 3 times to 10 times the upper limit of normal, and any AST and ALT).  Close monitoring of LFTs is recommended.', '2', '"Product Information. Yondelis (trabectedin)." Janssen Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29496, 29805, 'Trabectedin', 'Sepsis', 'The use of trabectedin has been associated with neutropenic sepsis, including fatal cases.  It is recommended to monitor neutrophil count before each dose of trabectedin and periodically during treatment.  Withhold treatment if the neutrophil count is less than 1,500 cells/microliter on the treatment day and permanently reduce the dose for life-threatening or prolonged, severe neutropenia in the preceding cycle.  Therapy with trabectedin should be administered cautiously in patients predisposed to neutropenia.  Patients should be warned to report any febrile illness.', '2', '"Product Information. Yondelis (trabectedin)." Janssen Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29497, 29805, 'Trabectedin', 'Rhabdomyolysis', 'Rhabdomyolysis and musculoskeletal toxicity can occur with the use of trabectedin.  It is recommended to obtain baseline serum creatine phosphokinase (CPK) and creatinine levels prior to initiating therapy with trabectedin and periodically during treatment as clinically indicated.  Withhold trabectedin for serum CPK levels more than 2.5 times the upper limit of normal.  If CPK is elevated, evaluate for signs and symptoms of rhabdomyolysis or other causes.  Permanently discontinue treatment for rhabdomyolysis.  Care should be taken when using this agent in patients at risk for rhabdomyolysis.', '2', '"Product Information. Yondelis (trabectedin)." Janssen Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29498, 29805, 'Trabectedin', 'Kidney Failure, Chronic', 'The use of trabectedin in patients with mild or moderate renal impairment is not expected to cause clinically significant effects on its pharmacokinetics.  No dose adjustment is recommended in patients with mild or moderate renal impairment.  The effects of severe renal impairment or end-stage renal disease on trabectedin exposure are unknown.  Hemodialysis is not expected to enhance the elimination of trabectedin as the product is highly bound to plasma proteins (97%) and not significantly excreted by the kidneys.', '2', '"Product Information. Yondelis (trabectedin)." Janssen Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29499, 15517, 'Benzonatate', 'Mental Disorders', 'Caution should be used when prescribing antitussives such as benzonatate in patients with psychiatric or emotional conditions.  Isolated instances of bizarre behavior, including mental confusion and visual hallucinations have been reported in patients taking antitussives, especially when combined with other prescribed drugs such as monoamine oxidase inhibitors.', '2', '"Product Information. Tessalon (benzonatate)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29500, 23756, 'Benzonatate', 'Mental Disorders', 'Caution should be used when prescribing antitussives such as benzonatate in patients with psychiatric or emotional conditions.  Isolated instances of bizarre behavior, including mental confusion and visual hallucinations have been reported in patients taking antitussives, especially when combined with other prescribed drugs such as monoamine oxidase inhibitors.', '2', '"Product Information. Tessalon (benzonatate)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
